Vinpocetine - instructions for use, dose, side effects, contraindications

Excipients: sodium carboxymethyl starch 10 mg, corn starch 39 mg, lactose monohydrate 80 mg, magnesium stearate 1 mg, talc 5 mg, microcrystalline cellulose 40 mg.

Description:

Tablets are white or almost white in color, round, flat, with a facet and with a risk on one side.

Pharmacotherapeutic group:Cerebral blood flow improver

ATX: & nbsp

N.06.B.X.18 Vinpocetine

Pharmacodynamics:

Vinpocetine selectively inhibits potential-dependent Na ⁺ channels, causing a dose-dependent decrease in Ca concentration²⁺ in the endings of neurons of the striatum. It is believed that the reduction in current Na⁺ has a neuroprotective effect due to a decrease in excitotoxicity and a weakening of neuronal damage caused by cerebral ischemia or reperfusion.

Vinpocetine increases the concentration of 3,4-dihydroxyphenylacetic acid (dopamine metabolite) in the nerve endings of the striatum. This action is similar to the pharmacological action of reserpine (reminiscent of the chemical structure vinpocetine), which depletes the supplies of catecholamines in the nerve endings of the brain, which causes side effects from the cardiovascular system (SSS) and the antipsychotic effect.

It also inhibits phosphodiesterase-1 (PDE-1), which leads to an increase concentrations intracellular guanosine monophosphate (cGMP). This leads to relaxation smooth muscle vessels of the brain.

Pharmacokinetics:

When ingested quickly and completely absorbed in the gastrointestinal tract (GIT) (mainly in the proximal parts of the small intestine). Bioavailability when taken on an empty stomach - about 7%. The maximum concentration (TC_m_Oh) in blood plasma - 1 hour, in tissues - 2 4 hours. When passing through the wall of the intestine is not exposed to metabolism. When introduced repeated doses kinetics is linear.

The connection with plasma proteins - 66%, clearance - 66.7 l / h, exceeds the hepatic clearance (50 l / h), which indicates extrahepatic metabolism.Penetrates into breast milk (0.25% within 1 hour), through the placental barrier. Half-life (T_1/2) - 3.54-6.12 h. It is excreted by the kidneys and intestines in the ratio 3: 2.

Indications:

Neurology (as part of complex therapy): as a symptomatic tool for various forms of cerebral circulatory insufficiency (ischemic stroke, reductive stage of hemorrhagic stroke, the consequences of a stroke; transient ischemic attack; vascular dementia; circulatory insufficiency in the vertebrobasilar basin; atherosclerosis of cerebral vessels; posttraumatic and hypertensive encephalopathy).

Ophthalmology: chronic vascular diseases of the choroid and retina (including occlusion of the central artery or vein of the retina).

Perceptive hearing loss, Meniere's disease, idiopathic tinnitus.

Contraindications:

Hypersensitivity, acute phase of hemorrhagic stroke, severe ischemic disease heart (IHD), severe heart rhythm disturbances, pregnancy, lactation, age up to 18 years.

Because the composition of the drug includes lactose monohydrate: lactose intolerance, deficiency lactases, glucose-galactose malabsorption.

Dosing and Administration:

Dosing and Administration Inside, after meals, the initial dose - 15 mg / day, the standard daily dose - 5-10 mg 3 times a day. The maximum daily dose is 30 mg. Course of treatment -1-3 months.

Side effects:

From the cardiovascular system: changes in the electrocardiogram (ECG) (segment depression ST, elongation Q-T interval); tachycardia, extrasystole (cause-and-effect relationship not established), lability of blood pressure (BP) (more often decline).

From the central nervous system: sleep disturbance (insomnia, increased drowsiness); dizziness, headache, general weakness (may be a manifestation of the underlying disease).

From the digestive system: dryness of the oral mucosa, nausea, heartburn.

Other: skin allergic reactions, increased sweating, skin hyperemia.

Overdose:

Symptoms: increased severity of side effects.

Treatment: gastric lavage, reception of activated charcoal, symptomatic treatment.

Interaction:

It is possible to intensify the hypotensive effect with simultaneous application with methyldopa (blood pressure control is necessary).

Special instructions:

In the case of the original elongation Q-T interval, as well as with simultaneous use with drugs that extend Q-T interval, during the treatment with vinpocetine periodic ECG monitoring is necessary.

Form release / dosage:

Tablets 5 mg.

Packaging:

By 5, 10, 15, 20, 25 or 50 tablets in a contour mesh box made of a polyvinylchloride film and aluminum foil.

According to 1, 2, 3, 4 or 5 contour packagings together with instructions for use place in a pack of cardboard.

By 30, 50, 60, 100 or 120 tablets into a container of high-density polyethylene with lid and control of the first autopsy.

1 container, together with the instruction for use, is placed in a pack of cardboard.

For 30, 50, 60, 100 or 120 tablets per package polyethylene.

1 package together with the instruction for use is placed in a container of polyethylene high density with a cover and control of the first autopsy.

Storage conditions:

Store in a dry, dark place at a temperature of no higher than 30 ° C.

Keep out of the reach of children.

Shelf life:

3 years.

Do not use after the expiration date printed on the package.

Terms of leave from pharmacies:On prescription

Registration number:P N014192 / 01-2002

Date of registration:07.08.2008

Expiration Date:Unlimited

The owner of the registration certificate:M. J. Biofarm Pvt. Ltd.M. J. Biofarm Pvt. Ltd. India

Manufacturer: & nbsp

M.J.Biofarm Pvt.Ltd India

Representation: & nbspM.J. BIOFARM Pvt. Ltd. division of the corporation MJ Group M.J. BIOFARM Pvt. Ltd. division of the corporation MJ Group India

Information update date: & nbsp17.02.2017

Illustrated instructions

Instructions

Vinpocetine (Vinpocetine)